{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:52:34Z","timestamp":1789815154897,"version":"4.0.1"},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.critrevonc.2018.04.002","type":"journal-article","created":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T16:29:23Z","timestamp":1523377763000},"page":"100-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Genomics and pharmacogenomics of pediatric acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"126","author":[{"given":"Chuan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2018.04.002_bib0005","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nri2304","article-title":"Molecular pathogenesis of T-cell leukaemia and lymphoma","volume":"8","author":"Aifantis","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0010","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1146\/annurev.pharmtox.42.082401.140850","article-title":"Challenges for biomedical informatics and pharmacogenomics","volume":"42","author":"Altman","year":"2002","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0015","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1517\/17425255.2012.658041","article-title":"The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury","volume":"8","author":"Amacher","year":"2012","journal-title":"Expert Opin. Drug. Metab. Toxicol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0020","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1365-2141.2012.09221.x","volume":"158","author":"Attarbaschi","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0025","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0022-3565(25)28700-6","article-title":"Daunomycin metabolism in rat tissue slices","volume":"175","author":"Bachur","year":"1970","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0030","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1182\/blood.V92.10.3569","article-title":"Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study","volume":"92","author":"Balis","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0035","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/ejh.12722","article-title":"Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment","volume":"96","author":"Bassan","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0040","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/S0140-6736(08)61341-0","article-title":"Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down\u2019s syndrome","volume":"372","author":"Bercovich","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0045","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the children\u2019s oncology group","volume":"23","author":"Berg","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0050","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a children's oncology group study","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0055","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2004-06-2498","article-title":"FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression","volume":"105","author":"Brown","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0060","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1053\/j.seminhematol.2008.09.002","article-title":"Pharmacogenetics in acute lymphoblastic leukemia","volume":"46","author":"Cheok","year":"2009","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0065","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/leu.2013.277","article-title":"An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions","volume":"28","author":"Clappier","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0070","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/nbt1239","article-title":"The MicroArray quality control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements","volume":"24","author":"Consortium","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0075","first-page":"1113","article-title":"Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia","volume":"91","author":"Costea","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0080","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0085","first-page":"1408","article-title":"Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia","volume":"45","author":"Daghestani","year":"1985","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0090","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/ng.2508","article-title":"Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia","volume":"45","author":"De Keersmaecker","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0095","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0100","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/sj.leu.2402373","article-title":"Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine","volume":"16","author":"Dervieux","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0105","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF00255486","article-title":"Can severe vincristine neurotoxicity be prevented?","volume":"8","author":"Desai","year":"1982","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0110","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev.med.56.082103.104724","article-title":"Pharmacogenomics and individualized drug therapy","volume":"57","author":"Eichelbaum","year":"2006","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0115","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jchromb.2003.08.006","article-title":"High-performance liquid chromatographic assay of metabolites of thioguanine and mercaptopurine in capillary blood","volume":"796","author":"Erb","year":"2003","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0120","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/leu.2009.249","article-title":"Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97","volume":"24","author":"Escherich","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0125","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature02626","article-title":"Moving towards individualized medicine with pharmacogenomics","volume":"429","author":"Evans","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0130","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0022-3476(05)83063-X","article-title":"Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia","volume":"119","author":"Evans","year":"1991","journal-title":"J. Pediatr."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0135","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0037-1963(00)90018-0","article-title":"Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia","volume":"37","author":"Ferrando","year":"2000","journal-title":"Semin Hematol"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0140","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/363358a0","article-title":"In utero rearrangements in the trithorax-related oncogene in infant leukaemias","volume":"363","author":"Ford","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0145","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1038\/onc.2013.169","article-title":"Small-molecule inhibition of CBP\/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia","volume":"33","author":"Gang","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0150","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/BF00446223","article-title":"Time dependency of adriamycin and adriamycinol kinetics","volume":"10","author":"Gil","year":"1983","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0155","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1203\/00006450-200207000-00021","article-title":"Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia","volume":"52","author":"Groninger","year":"2002","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0160","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2141.2004.04948.x","article-title":"Childhood and adult leukaemia working P. Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia","volume":"125","author":"Harrison","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0165","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/leu.2013.317","article-title":"International workshop in childhood acute lymphoblastic L. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome","volume":"28","author":"Harrison","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0170","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/blood-2009-09-245944","article-title":"Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic\/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia","volume":"115","author":"Harvey","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0175","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00280-009-1184-5","article-title":"DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma","volume":"66","author":"Hedeland","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0180","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/nm.3665","article-title":"A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia","volume":"20","author":"Herranz","year":"2014","journal-title":"NatNat. Med."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0185","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1038\/ncomms4630","article-title":"The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes","volume":"5","author":"Huether","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0190","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/cpt1972136895","article-title":"Daunorubicin metabolism in acute nonlymphocytic leukemia","volume":"13","author":"Huffman","year":"1972","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0195","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01213011-200505000-00002","article-title":"A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination","volume":"15","author":"Hulot","year":"2005","journal-title":"Pharmacogenet. Genom."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0200","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V87.4.1211.bloodjournal8741211","article-title":"Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis","volume":"87","author":"Hunger","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0205","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","article-title":"Acute lymphoblastic leukaemia","volume":"381","author":"Inaba","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0210","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/nature04226","article-title":"A haplotype map of the human genome","volume":"437","author":"International HapMap C","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0215","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2013-07-453480","article-title":"How I treat ALL in Down's syndrome: pathobiology and management","volume":"123","author":"Izraeli","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0220","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/cpt1978241101","article-title":"Biliary excretion of vincristine","volume":"24","author":"Jackson","year":"1978","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0225","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/bjh.13924","article-title":"Personalization of dexamethasone therapy in childhood acute lymphoblastic leukaemia","volume":"173","author":"Jackson","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0230","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1172\/JCI22477","article-title":"Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics","volume":"115","author":"Kager","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0235","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/blood.V90.7.2723","article-title":"In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia","volume":"90","author":"Kaspers","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0240","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/nbt869","article-title":"Large-scale genotyping of complex DNA","volume":"21","author":"Kennedy","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0245","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1002\/1097-0142(19931015)72:8<2423::AID-CNCR2820720821>3.0.CO;2-P","article-title":"Loss of constitutional heterozygosity on chromosome 11p in human ovarian cancer. Positive correlation with grade of differentiation","volume":"72","author":"Kiechle-Schwarz","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0250","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1182\/blood-2006-10-054528","article-title":"Ancestry and pharmacogenetics of antileukemic drug toxicity","volume":"109","author":"Kishi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0255","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1200\/JCO.2009.22.2950","article-title":"Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia consortium study","volume":"28","author":"Ko","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s004180000165","article-title":"The molecular basis of glucocorticoid-induced apoptosis of lymphoblastic leukemia cells","volume":"114","author":"Kofler","year":"2000","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0265","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1056\/NEJM199007053230104","article-title":"Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children","volume":"323","author":"Koren","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0270","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(02)08065-0","article-title":"Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia","volume":"359","author":"Krajinovic","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0275","first-page":"353","article-title":"Thymidylate synthase gene polymorphism and its association with relapse in childhood B-cell precursor acute lymphoblastic leukemia","volume":"88","author":"Lauten","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0280","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.3324\/haematol.2013.095372","article-title":"Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion","volume":"98","author":"Lengline","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0285","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF02220605","article-title":"The clinical pharmacology of 6-mercaptopurine","volume":"43","author":"Lennard","year":"1992","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0290","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1600-0609.2011.01695.x","article-title":"Nordic society of paediatric H and oncology. Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate\/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia","volume":"88","author":"Levinsen","year":"2012","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0295","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature13115","article-title":"Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia","volume":"508","author":"Li","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0300","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2012-02-265884","article-title":"How I treat relapsed childhood acute lymphoblastic leukemia","volume":"120","author":"Locatelli","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0305","doi-asserted-by":"crossref","first-page":"6604","DOI":"10.1038\/ncomms7604","article-title":"Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia","volume":"6","author":"Ma","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0310","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1038\/leu.2015.107","article-title":"KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia","volume":"29","author":"Malinowska-Ozdowy","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0315","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1038\/ncomms4469","article-title":"Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia","volume":"5","author":"Mar","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0320","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1182\/blood-2012-03-415448","article-title":"Targeting JAK1\/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"120","author":"Maude","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0325","doi-asserted-by":"crossref","first-page":"5776","DOI":"10.1016\/S0021-9258(19)70697-8","article-title":"Enzymatic synthesis of folylpolyglutamates. Characterization of the reaction and its products","volume":"255","author":"McGuire","year":"1980","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0330","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrg2841","article-title":"Advances in understanding cancer genomes through second-generation sequencing","volume":"11","author":"Meyerson","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0335","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood-2009-07-232124","article-title":"A population-based cytogenetic study of adults with acute lymphoblastic leukemia","volume":"115","author":"Moorman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0340","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1200\/JCO.2013.48.9377","article-title":"Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97\/99 and UKALL2003 trials","volume":"31","author":"Moorman","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0345","doi-asserted-by":"crossref","first-page":"8242","DOI":"10.1073\/pnas.112218799","article-title":"Chromosome translocations and covert leukemic clones are generated during normal fetal development","volume":"99","author":"Mori","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0350","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/gcc.22163","article-title":"Acute lymphoblastic leukemia with low hypodiploid\/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%","volume":"53","author":"Muhlbacher","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0355","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nature05690","article-title":"Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia","volume":"446","author":"Mullighan","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0360","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0365","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ng.469","article-title":"Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia","volume":"41","author":"Mullighan","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0370","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature09727","article-title":"CREBBP mutations in relapsed acute lymphoblastic leukaemia","volume":"471","author":"Mullighan","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0375","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2006-07-038299","article-title":"Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia","volume":"110","author":"Nachman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0380","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.clpt.2003.12.001","article-title":"Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity","volume":"75","author":"Nygaard","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0385","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood-2014-03-560847","article-title":"Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003","volume":"124","author":"O\u2019Connor","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0390","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.blre.2010.09.004","article-title":"Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia","volume":"25","author":"Paganin","year":"2011","journal-title":"Blood Rev."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0395","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.3324\/haematol.2013.099077","volume":"98","author":"Palmi","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0400","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ng.2874","article-title":"RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia","volume":"46","author":"Papaemmanuil","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0405","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/gcc.20613","article-title":"The complex genomic profile of ETV6-RUNX1 positive acute lymphoblastic leukemia highlights a recurrent deletion of TBL1XR1","volume":"47","author":"Parker","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0410","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/MOP.0b013e32833fde85","article-title":"Pharmacogenomics in pediatric leukemia","volume":"22","author":"Paugh","year":"2010","journal-title":"Curr. Opin. Pediatr."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0415","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1093\/jnci\/djt230","article-title":"The novel susceptibility variants for childhood acute lymphoblastic leukemia","volume":"105","author":"Perez-Andreu","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0420","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2014-09-595744","article-title":"A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults","volume":"125","author":"Perez-Andreu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0425","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/bjh.12063","article-title":"Genetic polymorphisms in ARID5B, CEBPE, IKZF1 and CDKN2A in relation with risk of acute lymphoblastic leukaemia in adults: a group for research on adult acute lymphoblastic leukaemia (GRAALL) study","volume":"159","author":"Peyrouze","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0430","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","article-title":"A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial","volume":"370","author":"Pieters","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11684-015-0381-3","article-title":"Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia","volume":"9","author":"Pui","year":"2015","journal-title":"Front. Med."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0440","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/sj.leu.2402883","article-title":"Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements","volume":"17","author":"Pui","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0445","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0450","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-05-378943","article-title":"Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?","volume":"120","author":"Pui","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0455","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1200\/JCO.1990.8.8.1380","article-title":"Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1;19)","volume":"8","author":"Raimondi","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/gr.129668.111","article-title":"Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition","volume":"22","author":"Ramsey","year":"2012","journal-title":"Genome Res."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0465","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1182\/blood-2012-08-452839","article-title":"Genome-wide study of methotrexate clearance replicates SLCO1B1","volume":"121","author":"Ramsey","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0470","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clpt.2006.08.012","article-title":"High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations","volume":"80","author":"Rau","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0475","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/asheducation-2013.1.126","article-title":"Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy","volume":"2013","author":"Relling","year":"2013","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0480","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/clpt.1992.203","article-title":"Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities","volume":"52","author":"Relling","year":"1992","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0485","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood.V93.9.2817.409k04_2817_2823","article-title":"Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia","volume":"93","author":"Relling","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0490","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0140-6736(00)02503-4","article-title":"Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia","volume":"356","author":"Relling","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0495","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/pbc.21435","article-title":"Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients","volume":"50","author":"Renbarger","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0500","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nrclinonc.2015.38","article-title":"Genomics in acute lymphoblastic leukaemia: insights and treatment implications","volume":"12","author":"Roberts","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0505","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2014.55.4105","article-title":"Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease","volume":"32","author":"Roberts","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0510","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0515","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1182\/blood-2004-11-4544","article-title":"Pharmacogenetics of outcome in children with acute lymphoblastic leukemia","volume":"105","author":"Rocha","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0520","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00004836-200303000-00010","article-title":"Hepatotoxicity associated with 6-thioguanine therapy for Crohn\u2019s disease","volume":"36","author":"Rulyak","year":"2003","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0525","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1182\/blood-2009-03-208397","article-title":"Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia","volume":"114","author":"Russell","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0530","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0140-6736(81)92623-4","article-title":"Differences in prognosis for boys and girls with acute lymphoblastic leukaemia","volume":"1","author":"Sather","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0535","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2141.2009.07765.x","article-title":"Advances in individual prediction of methotrexate toxicity: a review","volume":"146","author":"Schmiegelow","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0540","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/leu.2008.316","article-title":"Nordic society of paediatric H and oncology. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study","volume":"23","author":"Schmiegelow","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0545","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/MPH.0000000000000206","article-title":"Mercaptopurine\/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction","volume":"36","author":"Schmiegelow","year":"2014","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0550","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","article-title":"Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study","volume":"27","author":"Schultz","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0555","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2036.2012.05206.x","article-title":"Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism","volume":"36","author":"Shih","year":"2012","journal-title":"Aliment Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0560","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1200\/JCO.1996.14.1.18","article-title":"Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia","volume":"14","author":"Smith","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0565","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1371\/journal.pmed.0050083","article-title":"In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile","volume":"5","author":"Sorich","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0570","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/cncr.28522","volume":"120","author":"Soverini","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0575","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1001\/jama.293.12.1485","article-title":"Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia","volume":"293","author":"Stanulla","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0580","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/asheducation-2010.1.21","article-title":"Adolescents and young adults with acute lymphoblastic leukemia","volume":"2010","author":"Stock","year":"2010","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0585","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1002\/cncr.29573","article-title":"Childhood acute lymphoblastic leukemia: integrating genomics into therapy","volume":"121","author":"Tasian","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0590","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1158\/0008-5472.CAN-06-3993","article-title":"Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia","volume":"67","author":"Taylor","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0595","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2008-12-192039","article-title":"WT1 mutations in T-ALL","volume":"114","author":"Tosello","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0600","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.1200\/JCO.2008.20.4156","article-title":"Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects","volume":"27","author":"Trevino","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0605","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.cell.2014.05.049","article-title":"Genome-wide mapping and characterization of notch-regulated long noncoding RNAs in acute leukemia","volume":"158","author":"Trimarchi","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0610","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nm.3078","article-title":"Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL","volume":"19","author":"Tzoneva","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0615","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1200\/JCO.1995.13.7.1777","article-title":"Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies","volume":"13","author":"Uziely","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0620","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/ng.542","article-title":"PHF6 mutations in T-cell acute lymphoblastic leukemia","volume":"42","author":"Van Vlierberghe","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0625","first-page":"589","article-title":"Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors","volume":"66","author":"Villikka","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0630","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","article-title":"Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial","volume":"14","author":"Vora","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0635","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1200\/JCO.2012.47.6770","article-title":"Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia","volume":"31","author":"Weston","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0640","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1172\/JCI110472","article-title":"Cytosine arabinoside influx and nucleoside transport sites in acute leukemia","volume":"69","author":"Wiley","year":"1982","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0645","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/pbc.25470","article-title":"Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: children's oncology group study AALL0434","volume":"62","author":"Winter","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0650","doi-asserted-by":"crossref","DOI":"10.1158\/1055-9965.EPI-16-0722","article-title":"Adolescents and Young adults with acute lymphoblastic leukemia and acute myeloid leukemia: impact of care at specialized cancer centers on survival outcome","author":"Wolfson","year":"2017","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0655","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1200\/JCO.2007.13.8404","article-title":"Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia","volume":"26","author":"Yang","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0660","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/leu.2009.277","article-title":"ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence","volume":"24","author":"Yang","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0665","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1073\/pnas.0911726107","article-title":"Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia","volume":"107","author":"Yoda","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0670","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2011-03-341412","article-title":"Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the children's oncology group","volume":"118","author":"Zhang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.04.002_bib0675","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early t-cell precursor acute lymphoblastic leukaemia","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818301008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818301008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T15:22:07Z","timestamp":1751556127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842818301008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":135,"alternative-id":["S1040842818301008"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.04.002","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomics and pharmacogenomics of pediatric acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}